Quartet Finds A Solo Buyer In Merck Option Deal
This article was originally published in Scrip
Executive Summary
Quartet Medicine could provide investors in its earlier $17m Series A venture capital round a substantial return on investment through a new partnership with Merck & Co. Inc. to develop novel medicines for pain and inflammation in which the big pharma has an option to buy the biotech firm for up to $575m.